

Activity Outline
FDA Drug Topics: Biosimilar and Interchangeable Biological Products: An Updated Review of Scientific Concepts and Practical Resources
January 19, 2021
FDA

Activity Coordinator:

Kimberly DeFronzo (Kimberly.Defronzo@fda.hhs.gov), Kara Burke (Kara.Burke@fda.hhs.gov), Lesley Navin (Lesley.Navin@fda.hhs.gov), Thanh Tam Nguyen-Chu (thanh.nguyen-chu@fda.hhs.gov),

Description

This webinar will provide an intermediate overview of the scientific concepts about biological products and the scientific and regulatory basis for the biosimilar pathway. The webinar will build on past biosimilar webinars and further explores the science of biological molecules, including size, complexity, and structure. In addition, we will review practical information regarding the use of these products, such as labeling, terminology, and pharmacy substitution. To enhance understanding, we will review a case study to highlight the data that can support biosimilarity. This webinar will also demonstrate the functionality of the enhanced Purple Book resource that is available to health care professionals.

References

- Purple Book: Database of Licensed Biological Products: www.fda.gov/purplebooksearch
- Cohen, H.P., Blauvelt, A., Rifkin, R.M. et al. "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes." *Drugs* 78, 463–478 (2018). <https://doi.org/10.1007/s40265-018-0881-y>
- Datta-Mannan. "Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides." *CPT Pharmacometrics Syst Pharmacol.* 2017;6(9):576-588. doi:10.1002/psp4.12224
- Walsh, G. "Biopharmaceutical benchmarks 2018." *Nat Biotechnol* 36, 1136–1145 (2018). <https://doi.org/10.1038/nbt.4305>
- Guidance for Industry: Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products. November 2019. <https://www.fda.gov/media/133014/download>
- Oncology Drugs Advisory Committee meeting on October 10, 2018. Meeting materials: <https://www.fda.gov/advisory-committees/advisory-committee-calendar/meeting-oncologic-drugs-advisory-committee-10102018-10102018#event-materials>

Learning Objectives

- Describe how biologics differ from small molecules (size, complexity, manufacturing) and explain why some biologics cannot be copied exactly.
- Compare and contrast the development, statutory requirements, and approval process for new biologics and for biosimilars/interchangeables.
- Compare and contrast the requirements for generics and biosimilar/interchangeables and discuss the availability of insulin products.
- Review a case study of an approved biosimilar product.
- Describe and explain the new resources available for health care providers to learn more about biosimilar and interchangeable products through the enhanced Purple Book and other FDA educational resources.

Target Audience

This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, Certified Public Health Professionals (CPH), and physician assistants.

Agenda

Day 1 January 19, 2021

Time	Topic	Speaker
1:00 - 2:00 PM	FDA Drug Topics: Biosimilar and Interchangeable Biological Products: An Updated Review of Scientific Concepts and Practical Resources	Leila Hann Sarah Ikenberry, MA Nina Brahme, PhD, MPH

Continuing Education Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-21-002-L03-P, and ACPE Universal Activity Number JA0002895-0000-21-002-L03-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

AAPA

This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for Receiving CE Credit

Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- ▣ Brahme, Nina, PhD, MPH, Clinical Analyst, Food and Drug Administration *May reference off-label use.*
- ▣ Hann, Leila, Science Policy Analyst, FDA - nothing to disclose
- ▣ Ikenberry, Sarah, MA, Health Communication Specialist, CDER/OND/OTBB - nothing to disclose

Planning Committee

- ▣ Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- ▣ Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV - nothing to disclose
- ▣ DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
- ▣ Kapoor, Rama, MD, Medical Officer, FDA - nothing to disclose
- ▣ Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI - nothing to disclose
- ▣ Nguyen-Chu, Thanh Tam, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose

CE Consultation and Accreditation Team

- ▣ Lisa Thompson, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Registration Fee and Refunds

Registration is required for this activity, please reach out to the registration contact listed below for more information.

Registration is complimentary, therefore refunds are not applicable.

Requirements for Certificate of Completion (Non CE)

Must attend 100% of the activity.